The Role of NT-proBNP in the Diagnosis of Ventricular Arrhythmias in Patients with Systemic
-
Lucian MURESAN
,
Ana PETCU
,
Crina MURESAN
,
Mirela RINZIS
,
Gabriel GUSETU
,
Dana POP
,
Dumitru ZDRENGHEA
,
Simona REDNIC
Abstract
Background: In patients with systemic sclerosis, NT-proBNP is a useful diagnostic marker for pulmonary hypertension and ventricular dysfunction, with important prognostic significance. The aim of this study was to assess the relationship between the NT-proBNP levels and the presence and severity of ventricular arrhythmias in patients with scleroderma.
Methods: Forty consecutive patients with a diagnostic of systemic sclerosis according to the EULAR criteria admitted at the Rheumatology Clinic of Cluj-Napoca, Romania, from Jan 2014 to Apr 2014 were enrolled. Patients underwent a 12-lead ECG and a 24-hour Holter ECG monitoring for ventricular arrhythmias evaluation. Blood sample testing (including NT-proBNP level measurements), echocardiography, spirometry, chest X-ray and, when considered appropriate, high-resolution chest CT were performed.
Results: Sixty percent of patients (n=24) had abnormal NT-proBNP serum levels (>125 pg/ml) and 10 patients had >100 PVC /24 h. There was a statistically significant correlation between the NT-proBNP levels and the total number of premature ventricular contractions (PVC) (r=0.445, P=0.006), total number of isolated PVC (r=0,493, P=0.002), total number of ventricular couplets (r=0.379, P=0.021) and the number of PVC morphologies (r=0.501, P=0.002). The presence of an NT-proBNP serum level >287 pg/ml had a sensitivity of 55% and a specificity of 93% in predicting the presence of complex ventricular arrhythmias on 24-hour Holter ECG monitoring.
Conclusion: NT-proBNP levels could become a useful ventricular arrhythmia marker for assessing the arrhythmic risk in patients with systemic sclerosis.
Tsai SH, Lin YY, Chu SJ, Hsu CW, Cheng SM (2010). Interpretation and use of natriuretic peptides in non-congestive heart failure settings. Yonsei Med J, 51:151-63.
Berger R, Huelsman M, Strecker K, et al (2002). B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation, 105:2392-7.
Bayes-Genis A, Santalo-Bel M, Zapico-Muniz E, et al (2004). N-terminal probrain natriuretic peptide (NT-proBNP) in the emergency diagnosis and in-hospital monitoring of patients with dyspnoea and ventricular dysfunction. Eur J Heart Fail, 6:301-8.
van Kimmenade RR, Bakker JA, Crijns HJ, et al (2004). The value of (NT-pro) BNP in the diagnosis, prognosis and treatment of congestive heart failure. Neth Heart J, 12:61-63.
McDonagh TA, Holmer S, Raymond I, et al (2004). NT-proBNP and the diagnosis of heart failure: a pooled analysis of three European epidemiological studies. Eur J Heart Fail, 6:269-73.
Lerman A, Gibbons RJ, Rodeheffer RJ, et al (1993). Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left-ventricular dysfunction. Lancet, 341:1105-9.
Ogawa A, Seino Y, Yamashita T, Ogata K, Takano T (2006). Difference in elevation of N-terminal pro-BNP and conventional cardiac markers between patients with ST elevation vs non-ST elevation acute coronary syndrome. Circ J, 70:1372-8.
Ollivier JP, Revel F (2004). [Brain natriuretic peptide in acute coronary syndromes: utility of NT-proBNP assay]. Bull Acad Natl Med, 188:1529-38.
Galvani M, Ferrini D, Ottani F (2004). Natriuretic peptides for risk stratification of patients with acute coronary syndromes. Eur J Heart Fail, 6:327-33.
Schellings DA, Adiyaman A, Giannitsis E, et al (2014). Early discharge after primary percutaneous coronary intervention: the added value of N-terminal pro-brain natriuretic peptide to the Zwolle Risk Score. J Am Heart Assoc, 3:e001089.
Ma J, Xin Q, Wang X, Gao M, Wang Y, Liu J (2015). Prediction of perioperative cardiac events through preoperative NT-pro-BNP and cTnI after emergent non-cardiac surgery in elderly patients. PLoS One, 10:e0121306.
Kallistratos MS, Dritsas A, Laoutaris ID, Cokkinos DV (2007). N-terminal prohormone brain natriuretic peptide as a marker for detecting low functional class patients and candidates for cardiac transplantation: linear correlation with exercise tolerance. J Heart Lung Transplant, 26:516-21.
Garcia S, Akbar MS, Ali SS, et al (2010). N-terminal pro B-type natriuretic peptide predicts mortality in patients with left ventricular hypertrophy. Int J Cardiol, 143:349-52.
Pruszczyk P (2005). N-terminal pro-brain natriuretic peptide as an indicator of right ventricular dysfunction. J Card Fail, 11:S65-9.
Yap LB (2004). B-type natriuretic Peptide and the right heart. Heart Fail Rev, 9:99-105.
Chadha DS, Karthikeyan G, Goel K, et al (2010). N-terminal pro-BNP plasma levels before and after percutaneous transvenous mitral commissurotomy for mitral stenosis. Int J Cardiol, 144:238-40.
Bergler-Klein J (2009). Natriuretic peptides in the management of aortic stenosis. Curr Cardiol Rep, 11:85-93.
Mlczoch E, Darbandi-Mesri F, Luckner D, Salzer-Muhar U (2012). NT-proBNP in acute childhood myocarditis. J Pediatr, 160:178-9.
Kahveci G, Bayrak F, Mutlu B, et al (2007). Prognostic value of N-terminal pro-B-type natriuretic peptide in patients with active infective endocarditis. Am J Cardiol, 99:1429-33.
Pakula D, Marek B, Kajdaniuk D, et al (2011). Plasma levels of NT-pro-brain natriuretic peptide in patients with overt and subclinical hyperthyroidism and hypothyroidism. Endokrynol Pol, 62:523-8.
Wang F, Wu Y, Tang L, et al (2012). Brain natriuretic peptide for prediction of mortality in patients with sepsis: a systematic review and meta-analysis. Crit Care, 16:R74.
Gardner RS, Ozalp F, Murday AJ, Robb SD, McDonagh TA (2003). N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J, 24:1735-43.
Cavagna L, Caporali R, Klersy C, et al (2010). Comparison of brain natriuretic peptide (BNP) and NT-proBNP in screening for pulmonary arterial hypertension in patients with systemic sclerosis. J Rheumatol, 37:2064-70.
Allanore Y, Meune C (2009). N-terminal pro brain natriuretic peptide: the new cornerstone of cardiovascular assessment in systemic sclerosis. Clin Exp Rheumatol, 27(3 Suppl 54):59-63.
Simeoni S, Lippi G, Puccetti A, et al (2008). N-terminal pro-BNP in sclerodermic patients on bosentan therapy for PAH. Rheumatol Int, 28:657-60.
Mathai SC, Bueso M, Hummers LK, et al (2010). Disproportionate elevation of N-terminal pro-brain natriuretic peptide in scleroderma-related pulmonary hypertension. Eur Respir J, 35:95-104.
Levine YC, Rosenberg MA, Mittleman M, et al (2014). B-type natriuretic peptide is a major predictor of ventricular tachyarrhythmias. Heart Rhythm, 11:1109-16.
Simon T, Becker R, Voss F, et al (2008). Elevated B-type natriuretic peptide levels in patients with nonischemic cardiomyopathy predict occurrence of arrhythmic events. Clin Res Cardiol, 97:306-9.
Sutovsky I, Katoh T, Ohno T, et al (2004). Relationship between brain natriuretic peptide, myocardial wall stress, and ventricular arrhythmia severity. Jpn Heart J, 45:771-7.
Bhalla V, Willis S, Maisel AS (2004). B-type natriuretic peptide: the level and the drug--partners in the diagnosis of congestive heart failure. Congest Heart Fail, 10:3-27.
Ferreira S, Almeida R, Guerrero H, et al (2007). Prognosis of decompensated heart failure: role of NT-proBNP. Rev Port Cardiol, 26:535-45.
Mauritz GJ, Rizopoulos D, Groepenhoff H, et al (2011). Usefulness of serial N-terminal pro-B-type natriuretic peptide measurements for determining prognosis in patients with pulmonary arterial hypertension. Am J Cardiol, 108:1645-50.
Patton KK, Ellinor PT, Heckbert SR, et al (2009). N-terminal pro-B-type natriuretic peptide is a major predictor of the development of atrial fibrillation: the Cardiovascular Health Study. Circulation, 120:1768-74.
Gasparovic H, Burcar I, Kopjar T, et al (2010). NT-pro-BNP, but not C-reactive protein, is predictive of atrial fibrillation in patients undergoing coronary artery bypass surgery. Eur J Cardiothorac Surg, 37:100-5.
Sanna T, Sonaglioni A, Pieroni M, et al (2009). Baseline NT-Pro-BNP levels and arrhythmia recurrence in outpatients undergoing elective cardioversion of persistent atrial fibrillation: a survival analysis. Indian Pacing Electrophysiol J, 9:15-24.
Elshamy HA, Ibrahim SE, Farouk HM, et al(2011). N-terminal pro-brain natriuretic peptide in systemic sclerosis: new insights. Eur J Dermatol, 21:686-90.
Giallafos I, Triposkiadis F, Oikonomou E, et al (2014). Incident atrial fibrillation in systemic sclerosis: the predictive role of B-type natriuretic peptide. Hellenic J Cardiol, 55:313-21.
| Files | ||
| Issue | Vol 46 No 7 (2017) | |
| Section | Original Article(s) | |
| Keywords | ||
| Systemic sclerosis NT-proBNP Ventricular arrhythmias | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
